Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

213 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 213 results

Testing effectiveness (Phase 2)UnknownNCT03424759
What this trial is testing

Uncommon EGFR AZD9291

Who this might be right for
Non Small Cell Lung Cancer
Samsung Medical Center 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05498428
What this trial is testing

Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC 520
Large-scale testing (Phase 3)Study completedNCT00446225
What this trial is testing

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Who this might be right for
Non-Small Cell Lung Cancer
Spanish Lung Cancer Group 174
Testing effectiveness (Phase 2)UnknownNCT04974879
What this trial is testing

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT00503971
What this trial is testing

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Who this might be right for
Non-small Cell Lung Cancer
Spanish Lung Cancer Group 33
Early research (Phase 1)Active Not RecruitingNCT04141644
What this trial is testing

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
University of Utah 24
Not applicableLooking for participantsNCT06643000
What this trial is testing

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Henan Cancer Hospital 60
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Early research (Phase 1)Looking for participantsNCT07361237
What this trial is testing

A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Tongji University 36
Testing effectiveness (Phase 2)Looking for participantsNCT07070232
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 1,438
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319
What this trial is testing

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Not applicableStudy completedNCT04640870
What this trial is testing

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Who this might be right for
Non Small Cell Lung CancerEGF-R Positive Non-Small Cell Lung CancerEGFR Gene Mutation
Hellenic Cooperative Oncology Group 59
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Large-scale testing (Phase 3)Looking for participantsNCT07100080
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 500
Next Page
480